Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema AttacksNEW ENGLAND JOURNAL OF MEDICINEIF78.52024-07-0410PRE
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized TrialJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICEIF6.62024-03-014OAAI
Head & Neck Skin Cancer Figures 2020-in the Midst of the COVID-19 PandemicBRITISH JOURNAL OF SURGERYIF8.72023-08-300PRE
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical StudyAMERICAN JOURNAL OF CLINICAL DERMATOLOGYIF8.82023-05-1512OAAI
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: atwo-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialLANCETIF88.52023-02-0123PRE
Once-daily crisaborole as a long-term maintenance treatment in patients with mild-to-moderate atopic dermatitis: A 52-week clinical trialBRITISH JOURNAL OF DERMATOLOGYIF9.62023-01-250PRE
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and updateWORLD ALLERGY ORGANIZATION JOURNALIF4.32022-03-0153OAAI
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and updateALLERGYIF122022-02-03224OA
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study (vol 16, 86, 2021)ORPHANET JOURNAL OF RARE DISEASESIF3.52021-07-280OAAI
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22021-07-01100OAAI
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICEIF6.62021-06-0137OAAI
Safety Of Crisaborole In Patients Aged 3 To <24 Months With Mild-To-Moderate Atopic DermatitisPEDIATRICSIF6.42021-03-010OA
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyORPHANET JOURNAL OF RARE DISEASESIF3.52021-02-1523OAAI
Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and ExcellenceALLERGYIF122020-04-2734OAAI
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)AMERICAN JOURNAL OF CLINICAL DERMATOLOGYIF8.82020-03-2475OAAI
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findingsJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICEIF6.62019-07-0111OAAI
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized StudyJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICEIF6.62019-05-0112OAAI
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary AngioedemaJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICEIF6.62018-09-0169OAAI
RESPONSE TO SUBCUTANEOUS C1-ESTERASE INHIBITOR (C1-INH [SC]), A PROPHYLACTIC TREATMENT FOR ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA: RESULTS FROM THE PHASE 3 COMPACT TRIALJOURNAL OF ADOLESCENT HEALTHIF4.52018-02-011PREAI
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorNEW ENGLAND JOURNAL OF MEDICINEIF78.52017-03-23178OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向